PL3478712T3 - Przeciwciała przeciwko peptydowi amyloidu beta N3PGLU i ich zastosowania - Google Patents

Przeciwciała przeciwko peptydowi amyloidu beta N3PGLU i ich zastosowania

Info

Publication number: PL3478712T3
Authority: PL; Poland
Prior art keywords: amyloid beta; beta peptide; peptide antibodies; n3pglu amyloid; n3pglu
Prior art date: 2016-07-01

Application number

PL17736841.2T

Other languages

English (en)

Inventor

Ronald Bradley Demattos

Michael Carl IRIZARRY

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-01

Filing date

2017-06-23

Publication date

2023-11-06

2017-06-23 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2023-11-06 Publication of PL3478712T3 publication Critical patent/PL3478712T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17736841.2T 2016-07-01 2017-06-23 Przeciwciała przeciwko peptydowi amyloidu beta N3PGLU i ich zastosowania PL3478712T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662357579P	2016-07-01	2016-07-01
PCT/US2017/038999 WO2018005282A1 (en)	2016-07-01	2017-06-23	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number	Publication Date
PL3478712T3 true PL3478712T3 (pl)	2023-11-06

Family

ID=59295341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17736841.2T PL3478712T3 (pl)	2016-07-01	2017-06-23	Przeciwciała przeciwko peptydowi amyloidu beta N3PGLU i ich zastosowania

Country Status (28)

Country	Link
US (2)	US11312763B2 (pl)
EP (2)	EP3478712B1 (pl)
JP (4)	JP7165588B2 (pl)
KR (3)	KR20210024213A (pl)
CN (3)	CN114887054A (pl)
AU (1)	AU2017291414B2 (pl)
CA (1)	CA3029550C (pl)
DK (1)	DK3478712T5 (pl)
EA (1)	EA201892690A1 (pl)
ES (1)	ES2958508T3 (pl)
FI (1)	FI3478712T3 (pl)
HR (1)	HRP20230861T1 (pl)
HU (1)	HUE062980T2 (pl)
IL (1)	IL263788B2 (pl)
LT (1)	LT3478712T (pl)
MA (1)	MA45543B1 (pl)
MD (1)	MD3478712T2 (pl)
MX (2)	MX2018016066A (pl)
NZ (1)	NZ772768A (pl)
PL (1)	PL3478712T3 (pl)
PT (1)	PT3478712T (pl)
RS (1)	RS64386B1 (pl)
SG (1)	SG11201810371XA (pl)
SI (1)	SI3478712T1 (pl)
TW (2)	TWI735600B (pl)
UA (2)	UA127101C2 (pl)
WO (1)	WO2018005282A1 (pl)
ZA (1)	ZA201807633B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
TWI705975B (zh) *	2017-04-20	2020-10-01	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
EP3521308B1 (en) *	2018-01-31	2024-03-13	Vivoryon Therapeutics N.V.	Humanized and de-immunized antibodies
WO2019169448A1 (en) *	2018-03-09	2019-09-12	St Vincent's Institute Of Medical Research	Multi-specific antibodies
CA3107370A1 (en) *	2018-07-24	2020-01-30	Eisai R&D Management Co., Ltd.	Methods of treatment and prevention of alzheimer's disease
CN111184725B (zh) *	2020-02-27	2020-12-01	慈溪市人民医院医疗健康集团(慈溪市人民医院)	一种防治脑梗塞的药物制剂及其制备方法
TWI843040B (zh) *	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) *	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (en)	2021-05-24	2022-12-01	Eli Lilly And Company	Anti-amyloid beta antibodies and uses thereof
TW202334210A (zh) *	2021-10-29	2023-09-01	美商美國禮來大藥廠	靶向介白素-34之化合物及方法
KR20240105403A (ko) *	2021-10-29	2024-07-05	일라이 릴리 앤드 캄파니	인터류킨-34를 표적화하는 화합물 및 방법
AU2022376940A1 (en) *	2021-10-29	2024-05-02	Eli Lilly And Company	Compounds and methods targeting interleukin-34
AU2022376930A1 (en) *	2021-10-29	2024-05-02	Eli Lilly And Company	Compounds and methods targeting interleukin-34
KR102753583B1 (ko) *	2021-11-11	2025-01-10	의료법인 명지의료재단	Kras 특이적 활성화 t 세포 유도용 항원 조성물
WO2023146818A2 (en) *	2022-01-26	2023-08-03	T3D Therapeutics, Inc.	Methods of treating amyloid related brain disorders using novel compounds and antibodies
JP2025506411A (ja) *	2022-02-03	2025-03-11	イーライリリーアンドカンパニー	アルツハイマー病の診断及び治療のための局所タウイメージング
WO2025106313A1 (en)	2023-11-14	2025-05-22	Eli Lilly And Company	Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1397539A (en) *	1920-01-14	1921-11-22	Odell Risdon Moore	Egg-carton
IL151378A0 (en)	2000-02-24	2003-04-10	Univ Washington	Humanized antibodies that sequester amyloid beta peptide
US7122374B1 (en)	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1523499A2 (en)	2002-07-24	2005-04-20	Innogenetics N.V.	Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005025616A1 (ja)	2003-09-09	2005-03-24	Takeda Pharmaceutical Company Limited	抗体の用途
GEP20115195B (en)	2004-07-30	2011-04-11	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide and use thereof
CA2632828C (en)	2005-12-12	2012-07-10	F. Hoffmann-La Roche Ag	Antibodies against amyloid beta with glycosylation in the variable region
BRPI0709050B1 (pt)	2006-03-23	2018-12-26	Bioarctic Neuroscience Ab	anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
NZ574188A (en)	2006-07-14	2012-05-25	Ac Immune Sa	Humanized antibody against amyloid beta
CA2675847C (en)	2007-01-18	2014-12-30	Eli Lilly And Company	Pegylated a.beta. fab
SI2182983T1 (sl) *	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
WO2009149487A2 (en)	2008-06-12	2009-12-17	Affiris Ag	Compounds for treating symptoms associated with parkinson's disease
CA2730073A1 (en)	2008-07-09	2010-01-14	University Of Zurich	Method of promoting neurogenesis
EP3338795A1 (en)	2008-07-21	2018-06-27	Probiodrug AG	Diagnostic antibody assay
CN101397539B (zh) *	2008-10-14	2011-10-05	中国人民解放军第三军医大学	组织工程组织仿生培养的模拟人体生理应力的施力装置
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8795664B2 (en)	2010-06-04	2014-08-05	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (en)	2010-08-12	2012-02-16	Eli Lilly And Company	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
DK3339323T3 (da) *	2010-08-12	2020-01-20	Lilly Co Eli	Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
US9499610B2 (en)	2011-04-08	2016-11-22	H. Lundbeck A/S	Antibodies specific to pyroglutamated Aβ
BR112015013312A2 (pt)	2012-12-07	2017-11-14	Biogen Idec Int Neuroscience Gmbh	método para reduzir placas amiloides do cérebro usando anticorpos anti-abeta
TWI593692B (zh)	2013-03-12	2017-08-01	美國禮來大藥廠	四氫吡咯并噻嗪化合物
SG10201901076WA (en)	2014-02-08	2019-03-28	Genentech Inc	Methods of treating alzheimer's disease
WO2015175769A1 (en) *	2014-05-15	2015-11-19	Biogen Ma Inc.	Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en)	2014-06-13	2015-12-17	Biogen Ma Inc.	Methods for the detection and measurement of amyloid beta in biological samples
JP6201928B2 (ja) *	2014-08-04	2017-09-27	トヨタ自動車株式会社	車両制御装置
TWI570127B (zh)	2014-09-15	2017-02-11	美國禮來大藥廠	結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh)	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
WO2016053767A1 (en)	2014-09-30	2016-04-07	Merck Sharp & Dohme Corp.	Novel crystalline forms of a bace inhibitor, compositions, and their use
MA41115A (fr) *	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
JOP20170004B1 (ar)	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途

2017
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-23 IL IL263788A patent/IL263788B2/en unknown
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 DK DK17736841.2T patent/DK3478712T5/da active
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/en not_active Ceased
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active Ceased
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Withdrawn
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/en active Active
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active Active
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
- 2017-06-23 UA UAA202202998A patent/UA129392C2/uk unknown
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 NZ NZ772768A patent/NZ772768A/en unknown
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/en active Pending
- 2017-06-23 CA CA3029550A patent/CA3029550C/en active Active
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
2020
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending

Also Published As

Publication number	Publication date
AU2017291414A1 (en)	2018-12-13
CN114917338A (zh)	2022-08-19
US20220235122A1 (en)	2022-07-28
JP7165588B2 (ja)	2022-11-04
PT3478712T (pt)	2023-08-21
EP4272828A2 (en)	2023-11-08
CA3029550A1 (en)	2018-01-04
AU2017291414B2 (en)	2019-11-21
KR20230021773A (ko)	2023-02-14
MX2023001299A (es)	2023-02-22
EP4272828A3 (en)	2024-01-10
HUE062980T2 (hu)	2023-12-28
IL263788A (en)	2019-01-31
TWI798751B (zh)	2023-04-11
IL263788B2 (en)	2024-10-01
CA3029550C (en)	2023-08-22
TW201811363A (zh)	2018-04-01
JP2021059547A (ja)	2021-04-15
MA45543A (fr)	2019-05-08
MD3478712T2 (ro)	2024-01-31
UA129392C2 (uk)	2025-04-09
JP2023123503A (ja)	2023-09-05
EA201892690A1 (ru)	2019-05-31
DK3478712T5 (da)	2024-09-09
NZ748496A (en)	2021-02-26
US20190382471A1 (en)	2019-12-19
CN109415433A (zh)	2019-03-01
JP2019518783A (ja)	2019-07-04
IL263788B1 (en)	2024-06-01
FI3478712T3 (fi)	2023-10-02
TW202140544A (zh)	2021-11-01
JP2021059546A (ja)	2021-04-15
WO2018005282A1 (en)	2018-01-04
HRP20230861T1 (hr)	2023-11-10
BR112018073843A2 (pt)	2019-02-26
CN114887054A (zh)	2022-08-12
KR102221402B1 (ko)	2021-03-02
NZ772768A (en)	2024-11-29
ZA201807633B (en)	2021-05-26
EP3478712B1 (en)	2023-07-19
EP3478712A1 (en)	2019-05-08
RS64386B1 (sr)	2023-08-31
US11312763B2 (en)	2022-04-26
MX2018016066A (es)	2019-04-24
TWI735600B (zh)	2021-08-11
LT3478712T (lt)	2023-08-25
SG11201810371XA (en)	2018-12-28
UA127101C2 (uk)	2023-04-19
KR20210024213A (ko)	2021-03-04
KR20190012208A (ko)	2019-02-08
JP7241058B2 (ja)	2023-03-16
SI3478712T1 (sl)	2023-10-30
MA45543B1 (fr)	2023-08-31
DK3478712T3 (da)	2023-09-04
ES2958508T3 (es)	2024-02-09

Publication	Publication Date	Title
ZA202007868B (en)	2023-06-28	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
ZA201901207B (en)	2022-05-25	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL263788A (en)	2019-01-31	Anti-peptide n3pglu amyloid beta antibodies and their uses
IL290783A (en)	2022-04-01	Anti-tau antibodies and their uses
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and their uses
IL267942B (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
IL268734A (en)	2019-10-31	Anti-LAG-3 antibodies and uses thereof
IL268700A (en)	2019-10-31	Anti-PHF-tau antibodies and uses thereof
SG11202003652QA (en)	2020-05-28	Anti-galectin-9 antibodies and uses thereof
ZA201801943B (en)	2019-01-30	Anti¿lag3 antibodies and uses thereof
SG11201808632YA (en)	2018-10-30	Anti-pacap antibodies and uses thereof
IL269134A (en)	2019-11-28	Antibodies against PAR2 and their use
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
IL273157A (en)	2020-04-30	Antibodies specific to AXL and their uses
IL272476A (en)	2020-03-31	Anti-Apelin antibodies and their uses
IL266082A (en)	2019-06-30	Anti-chikv antibodies and their use
IL266049A (en)	2019-06-30	Antibodies against o1 and their uses
IL265383A (en)	2019-05-30	New antibodies against factor xi and their uses
IL262244A (en)	2018-11-29	Antibodies against beta interferon and their use
IL264417A (en)	2019-02-28	Anti-o2 antibodies and their uses
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof
HK40014019A (en)	2020-08-14	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
TH1801008154A (th)	2025-05-12	แอนติ-N3pGlu อะไมลอยด์เบต้าเปปไทด์แอนติบอดีและการใช้ของสิ่งนั้น
GB201519105D0 (en)	2015-12-16	Antibody polypeptides and uses thereof
GB201517550D0 (en)	2015-11-18	Antibody polypeptides and uses thereof